Publications Archives

egnite Expands Medical Advisory Board with Three Nationally Recognized Cardiovascular Specialists

June 18, 2026

New appointments add structural heart, cardiothoracic surgery, and real-world outcomes expertise to advance egnite’s cardiovascular intelligence platform ALISO VIEJO, Calif. — June 18, 2026 — egnite, Inc., a healthcare AI company focused on helping clinicians identify and manage patients with untreated heart disease, today announced the expansion of its Medical Advisory Board (MAB). Joining the MAB are three distinguished cardiovascular specialists: Vijay Iyer, MD, PhD, FACC, Chief

egnite Launches New Lp(a) Identification Capability to Accelerate Clinical Trial Enrollment

June 11, 2026

egnite’s CardioCare Research Suite now identifies Lp(a) patients at health system scale, helping clinical trial teams to successfully find patients with elevated Lp(a) who were previously undetected due to current limitations in technology and workflow.

egnite, Inc. Receives U.S. Patent for NLP-Based Algorithm That Classifies Mitral Regurgitation Mechanism from Echocardiographic Reports

April 6, 2026

egnite, Inc., a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD to its Medical Advisory Board. Their wealth of expertise in cardiovascular care and dedication to innovation will significantly contribute to egnite’s mission to

egnite Introduces Customer Access to Its National Cardiovascular Registry and Launches 2026 Call for Science Investigator-Initiated Study Program

February 24, 2026

Cath Lab Capacity is Up—But Structural Heart Procedures Are Being Outpaced by Other Interventions

September 30, 2025

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient